Purple Biotech Ltd. (PPBT)
Total Valuation
Purple Biotech has a market cap or net worth of $19.02 million. The enterprise value is $3.96 million.
Market Cap | 19.02M |
Enterprise Value | 3.96M |
Important Dates
The last earnings date was Tuesday, March 5, 2024, before market open.
Earnings Date | Mar 5, 2024 |
Ex-Dividend Date | n/a |
Share Statistics
Purple Biotech has 25.94 million shares outstanding.
Shares Outstanding | 25.94M |
Owned by Insiders (%) | 3.96% |
Owned by Institutions (%) | 9.16% |
Float | n/a |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | n/a |
Forward PS | n/a |
PB Ratio | 0.56 |
P/FCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
EV / Earnings | 0.20 |
EV / Sales | n/a |
EV / EBITDA | 0.18 |
EV / EBIT | 0.18 |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.20, with a Debt / Equity ratio of 0.01.
Current Ratio | 2.20 |
Quick Ratio | n/a |
Debt / Equity | 0.01 |
Debt / EBITDA | 0.02 |
Debt / FCF | n/a |
Interest Coverage | 10.06 |
Financial Efficiency
Return on equity (ROE) is 49.00% and return on invested capital (ROIC) is -64.45%.
Return on Equity (ROE) | 49.00% |
Return on Assets (ROA) | 41.70% |
Return on Capital (ROIC) | -64.45% |
Revenue Per Employee | n/a |
Profits Per Employee | $994,000 |
Employee Count | 20 |
Asset Turnover | n/a |
Inventory Turnover | n/a |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -61.93% in the last 52 weeks. The beta is 0.57, so Purple Biotech's price volatility has been lower than the market average.
Beta (1Y) | 0.57 |
52-Week Price Change | -61.93% |
50-Day Moving Average | 0.72 |
200-Day Moving Average | 1.04 |
Relative Strength Index (RSI) | 45.34 |
Average Volume (30 Days) | 100,696 |
Short Selling Information
Short Interest | 223,002 |
Short Previous Month | 295,900 |
Short % of Shares Out | 6.95% |
Short % of Float | n/a |
Short Ratio (days to cover) | 1.83 |
Income Statement
Revenue | n/a |
Gross Profit | n/a |
Operating Income | -22.27M |
Pretax Income | 19.88M |
Net Income | 19.88M |
EBITDA | 22.27M |
EBIT | 22.08M |
Earnings Per Share (EPS) | -$0.90 |
Balance Sheet
The company has $15.41 million in cash and $351,000 in debt, giving a net cash position of $15.06 million or $0.58 per share.
Cash & Cash Equivalents | 15.41M |
Total Debt | 351,000 |
Net Cash | 15.06M |
Net Cash Per Share | $0.58 |
Equity / Book Value | 34.21M |
Book Value Per Share | 1.32 |
Working Capital | 8.61M |
Cash Flow
In the last 12 months, operating cash flow was -$19.93 million and capital expenditures -$3,000, giving a free cash flow of -$19.93 million.
Operating Cash Flow | -19.93M |
Capital Expenditures | -3,000 |
Free Cash Flow | -19.93M |
FCF Per Share | -$1.01 |
Margins
Gross Margin | n/a |
Operating Margin | n/a |
Pretax Margin | n/a |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
Purple Biotech does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -11.37% |
Shareholder Yield | -11.37% |
Earnings Yield | 104.54% |
FCF Yield | -104.79% |
Analyst Forecast
The average price target for Purple Biotech is $10.00, which is 1,392.54% higher than the current price. The consensus rating is "Strong Buy".
Price Target | $10.00 |
Price Target Difference | 1,392.54% |
Analyst Consensus | Strong Buy |
Analyst Count | 4 |
Revenue Growth Forecast (5Y) | n/a |
EPS Growth Forecast (5Y) | n/a |
Stock Splits
The last stock split was on August 21, 2020. It was a reverse split with a ratio of 1:10.
Last Split Date | Aug 21, 2020 |
Split Type | Reverse |
Split Ratio | 1:10 |
Scores
Altman Z-Score | n/a |
Piotroski F-Score | 3 |